NCT06497010招募中早期 1 期
An Open Label, Prospective, Exploratory Study to Assess the Safety and Efficacy of Individualized Neo-antigen mRNA Cancer Vaccine InnoPCV in Combination With PD-1 in Participants With Advanced Solid Tumor
The Affiliated Hospital Of Guizhou Medical University1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2024年8月29日最近更新:
适应症
相关药物
试验速览
- 阶段
- 早期 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Recommended Phase 2 Dose (RP2D)
研究概览
简要总结
This is an open-label, prospective, exploratory clinical study, which is divided into two phases: dose escalation phase (Phase Ia) and expansion phase (Phase Ib). After completing the dose-escalation phase (Stage Ia) (5-11 patients), the investigator will select the dose group (RP2D) based on safety, tolerability, and preliminary immune-related characteristics and efficacy data, and choose 2-3 advanced solid tumors to enter the expansion phase (Stage Ib).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18-75 years, male or female.
- •Histologically/cytologically or clinically confirmed advanced unresectable protocol-specified solid malignancies.
- •Participants with Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.
- •Life expectation >= 12weeks.
- •Participants must have a formalin-fixed paraffin-embedded (FFPE) tumor sample available (for example, from their prior surgery) that is suitable for the next-generation sequencing (NGS) required for this study.
- •Adequate organ function.
- •Participants must agree to use adequate contraception from the first dose of study medication through 180 days after the last dose of study medication (male and female participants of childbearing potential).
排除标准
- •Not recovered to Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or better from the adverse events (except for alopecia, vitiligo, neurotoxicity, hypothyroidism hormone replacement therapy) caused by therapy administered within 4 weeks before the first dose of PD-
- •Participants with a history of (non-study tumor) malignancy (except for skin squamous cell carcinoma and basal cell carcinoma, in situ cervical or breast carcinoma) within 3 years before the first dose of PD-
- •Participation in a study of an investigational agent or using an investigational device within 30 days before the first dose of PD-
- •Previously received any adoptive cell therapy (including but not limited to tumor-infiltrating lymphocyte TILs, chimeric antigen receptor T cells (CAR-T) and T cell receptor chimeric T cells (TCR-T)), therapeutic tumor vaccines, etc.
- •Participants received chemotherapy, radiotherapy (palliative radiotherapy is allowed), and immune activator (including but not limited to IL-2) and other antitumor therapy within 21 days before the first dose; Participants received Chinese herbal medicine within 2 weeks before the first dose of PD-
- •Major surgery (excluding diagnostic biopsy) or significant trauma had not been fully recovered within 28 days before the first dose of PD-
- •Participants received live attenuated vaccine within 28 days before starting study treatment or planned to receive live attenuated vaccine during the study and within 60 days after ending the study drug treatment.
- •Active autoimmune disease or a documented history of autoimmune disease or the syndrome that requires systemic steroids or immunosuppressive agents, except vitiligo or resolved childhood asthma/atopy.
- •Positive for Human Immunodeficiency Virus (HIV), Hepatitis B (HBV-DNA≥ 500IU/ml), or Hepatitis C virus (Hepatitis C Virus Ribonucleic Acid [HCV RNA] (qualitative) is detected).
- •Previously identified hypersensitivity to components of the formulations used in this study.
结局指标
主要结局
Recommended Phase 2 Dose (RP2D)
时间窗: Baseline through 90 days after last InnoPCV dose
次要结局
- Number of Participants with Adverse Events(Baseline through 90 days after last tislelizumab or sintilimab dose)
- Neoantigen-specific T cell Response rate(Baseline through 26 weeks after last InnoPCV dose)
- Overall Survival (OS)(From baseline to approximately 2 years)
- Objective Response Rate (ORR): Number of Participants with Tumor Response (Partial or Complete)(Baseline through disease progression by Response Evaluation Criteria of Solid Tumors Version 1.1 (RECIST 1.1), start of new anti-cancer therapy, withdrawal of consent, death and last safety follow-up visit (up to approximately 2 years))
- Duration of Response (DoR)(Baseline through disease progression by Response Evaluation Criteria of Solid Tumors Version 1.1 (RECIST 1.1), start of new anti-cancer therapy, withdrawal of consent, death and last safety follow-up visit (up to approximately 2 years))
- Progression Free Survival (PFS)(From baseline to disease progression by Response Evaluation Criteria of Solid Tumors Version 1.1 (RECIST 1.1) or death (up to approximately 2 years))
研究者
Shengfa Su
Chief Physician
The Affiliated Hospital Of Guizhou Medical University
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLCAnti AngiogenesisNon-Small Cell Lung CancerNCT06475755Tang-Du Hospital178
已完成
1 期
A Study of the Effects of Food and Age on DanicopanHealthyNCT04551599Alexion Pharmaceuticals, Inc.27
尚未招募
2 期
A Phase II Trial to Explore Niraparib and Anlotinib Maintenance Retreatment in Platinum-Sensitive Recurrent Ovarian Cancer Patients Previously Treated With PARPiEpithelial Ovarian CancerNCT05385068Peking Union Medical College Hospital35
招募中
2 期
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALLACUTE LYMPHOBLASTIC LEUKEMIANCT05748171Pfizer100
招募中
2 期
Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II TrialMarginal Zone Lymphoma(MZL)NCT06700798Fei Li90